WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ — Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.